Industry landscapes
The companies, capital and talent shaping life sciences in the Netherlands. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
83 of 969 tracked companies have open roles.
302 of 969 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 493 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 17.8% of disclosed capital, while 68.8% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $98.53M | 60 | 34 |
| 2017 | $218.3M | 53 | 40 |
| 2018 | $317.63M | 43 | 40 |
| 2019 | $247.09M | 45 | 46 |
| 2020 | $532.46M | 54 | 53 |
| 2021 | $849.53M | 35 | 47 |
| 2022 | $352.22M | 27 | 40 |
| 2023 | $465.21M | 14 | 42 |
| 2024 | $429.67M | 8 | 25 |
| 2025 | $779.36M | 3 | 27 |
Share of all disclosed company funding.
616 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by EQT.
Backed by MIG Capital and ATHOS KG and others.
Backed by Insight Partners and Siemens Healthineers.
Backed by CARB-X.
Backed by .
Backed by Intervest and McPike Global Family Office and others.
Backed by Biovance Capital and Kurma Partners.
Backed by Demcon and Myosotisinvestments.
Backed by Kaiser Permanente and Medpace and others.
Backed by Jeito and Forbion and others.
Backed by Casdin Capital and Google Ventures and others.
Backed by EQT and Forbion and others.
Backed by Farallon Capital Management and Lauxera Capital Partners and others.
Backed by Johnson & Johnson Innovation – JJDC and Forbion and others.
Backed by Innovation Industries and Partners in Equity and others.
Backed by Sofinnova Investments and Rock Springs Capital and others.
Backed by Sanofi Ventures and Pureos Bioventures and others.
Backed by Viking Capital and General Atlantic and others.
No reviewed exact national-ID connector maps Netherlands company identities to the configured global filings table.; No reviewed exact national-ID connector maps Netherlands company identities to the configured global filings table.
How the the Netherlands companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
27 of these companies (2.8%) publish at least one Android app — 39 apps in all, carrying 134.3K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| VASCOYour Research | 34.8K | — | Medical |
| Van Raam E-BikeVan Raam | 26.3K | — | Health & Fitness |
| Your Research AppYour Research | 21.3K | — | Medical |
| iGene DNA testiGene | 12.6K | 3.5 | Health & Fitness |
| eLabNexteLabNext | 10.2K | — | Productivity |
| Studypages Data (Teamscope)Teamscope | 7.4K | — | Health & Fitness |
| are you okay todayAre you okay today | 3.6K | — | Health & Fitness |
| TN70 advice & support appTopigs Norsvin | 3.2K | — | Books & Reference |
| Nyquist CalculatorSVI Huygens | 1.9K | — | Tools |
| UMC Research AppYour Research | 1.9K | — | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Tech | 13 | 93.1K | VASCO 34.8K | |
| Assistive Tech | 4 | 30.6K | Van Raam E-Bike 26.3K | |
| Orthopedics | 7 | 27.4K | Intuy by Reboocon 530 | |
| Genomics | 6 | 17.7K | iGene DNA test 12.6K | |
| Livestock Tech | 3 | 4.3K | TN70 advice & support app 3.2K | |
| Disease Self Management | 2 | 3.7K | are you okay today 3.6K | |
| Healthcare It | 4 | 2.9K | eLabInventory 1.2K | |
| Cardiac And Vascular Disorders | 4 | 1.8K | SkinAge 732 |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 28 of 39 apps carry a release date. The series ends at 2025Q2, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
59 companies hiring · $4.57B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
ScreenPoint Medical raised $14M growth funding for breast imaging AI.
Nanomi has completed the full acquisition of VISUfarma B.V., Netherlands. Consequently, VISUfarma and its subsidiaries have become wholly owned subsidiaries of Nanomi effective April 1, 2026.
Funding for Startups ATRO Medical closed a €3 million (~USD $3.5 million) financing round.
NEW YORK — Automated phlebotomy firm Vitestro said Tuesday that it has raised $70 million in an oversubscribed Series B funding round.
Qiagen's deal to be acquired by Thermo Fisher Scientific in 2020 fell through, but the company had subsequently been rumored to be in talks with BioMérieux about a potential merger agreement.
In the Netherlands, QDI Systems obtained up to €7.5 million in investment and EIC support to advance quantum-dot-based X-ray and SWIR imaging technologies for medical and industrial applications.
Netherlands-based trials contractor Symeres acquiring drug development consultancy DGr Pharma to bolster its early-phase study offering.
Dutch startup TargED secured €21.5 million Series A extension to advance targeted treatments for thrombotic diseases.
Pan Cancer T, a biotech startup based in Rotterdam, has raised €10 million in funding to bring a next‑generation T‑cell therapy to patients with triple‑negative breast cancer (TNBC).
Now eight of the 12 businesses have each won £200,000 funding.
Top 10 categories among 313 recorded events in the 24-month window.
5 companies with recorded IPO activity
Follow-on Offering · Nasdaq1 reports
IPO · NASDAQ3 reports
IPO · Euronext Amsterdam, Nasdaq1 reports
IPO1 reports
IPO · Amsterdam Stock Exchange5 reports
16 tracked people moves
Appointment Chief Executive Officer
Appointment Chairman of the Board
Appointment Chief Executive Officer (CEO)
Appointment General Manager for France
Appointment Chief Executive Officer
Appointment Chief Accounting Officer
Appointment Independent Member, Supervisory Board
Resignation Chief Scientific Officer, Memorial Sloan Kettering Cancer Center
12 recorded customer wins
Customer: savon voimaEnergy
Customer: vir biotechnologyHealthcare
Customer: synergenicsBiotechnology
Customer: GlaxoSmithKline plcBiotechnology
Customer:
Customer: menarini group
9 recorded events
1 tracked suits
misrepresentation of pivotal study results leading to securities laws violationsSecurities Fraud · Filed
Reported company results in the recorded window.
Median across 35 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Nanomi→Multicare Pharmaceuticals Philippines Inc. | Announced | 2026-04-02 | $39.6M |
| Nanomi→visufarma | Completed | 2026-04-01 | Not stated in snapshot |
| thermo fisher scientific→Qiagen ↗ | Terminated | 2026-01-20 | Not stated in snapshot |
| Qiagen→BioMérieux | Rumored | 2026-01-20 | Not stated in snapshot |
| Qiagen→parse biosciences | Announced | 2026-01-20 | Not stated in snapshot |
| genmab→Merus ↗ | Announced | 2025-12-29 | $8.0B |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
1 postings in the preceding 12 months. The full 18-posting snapshot covers 12 employers.
0 tracked postings mention remote work.
4 postings specify a level.
| Company | Employees |
|---|---|
| Malvern Panalytical ↗ | 1,771 |
| Rousselot ↗ | 951 |
| Livit Orthopedie ↗ | 670 |
| UniQure ↗ | 501 |
| Pharming Group ↗ | 332 |
| LUMICKS ↗ | 263 |
| HAL Allergy Group ↗ | 255 |
| Van Raam ↗ | 245 |
610 founders and chief executives across 461 companies.
Ex-AngioDynamics, Smith & Nephew, Collins Stewart, Wells Fargo Securities, Robertson Stephens. University of Michigan BBA 1994…
Ex-Corvidia Therapeutics, Omthera Pharmaceuticals. Northwestern University 1978, The Ohio State University College of Medicine MD 1981
Chairman Marine Construction Technologies & Resolute Medical, JointMetrix Medical. UCLA MBA 2000
Ex-Cellnovo, Swanturbines. Swansea University 2007
Vectory, ex-Porton Biologics, ex-Leiden University Medical Center, University of Amsterdam, 2004
Ex- Ultragenyx Pharmaceutical, Celgene, Genzyme, Genzyme Europe, Sigma-tau. University of Naples Federico II MD 1987
Pharvaris, ex-Centogene, ex-Sio Gene Therapies, INSEAD, 1990
Ex-Pronova BioPharma Norge, Rikshospitalet. University of Aberdeen MSc 1994, University of Oslo PhD 2000
Citryll, ex-Sutura Therapeutics, ex-Ebac, INSEAD, 1991
Leiden University LLM 1987
University of Trieste 2004, Delft University of Technology MS 2007
Ex-Co-Founder & CEO Zarafa, Connectux, Arthur DLittle. Delft University of Technology MSc 1998
75 profiles with education records.
2 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
570 articles in the measured 12-month window.
Life Sciences coverage across Netherlands · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 89 |
| 2021Q3 | 107 |
| 2021Q4 | 171 |
| 2022Q1 | 157 |
| 2022Q2 | 136 |
| 2022Q3 | 81 |
| 2022Q4 | 146 |
| 2023Q1 | 102 |
| 2023Q2 | 147 |
| 2023Q3 | 157 |
| 2023Q4 | 149 |
| 2024Q1 | 156 |
| 2024Q2 | 149 |
| 2024Q3 | 119 |
| 2024Q4 | 148 |
| 2025Q1 | 574 |
| 2025Q2 | 119 |
| 2025Q3 | 106 |
| 2025Q4 | 151 |
| 2026Q1 | 196 |
Article volume measures coverage, not market sales.
412 recorded company events across 67 companies; percentages use that event total.
Life Sciences coverage across Netherlands · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across Netherlands
stem cell banking, cell-based meat, cultured meat
46.2% critical · 50.0% positivetherapeutic development funding, life sciences seed funding, dark nebulae
56.3% critical · 65.0% positivegene delivery systems, viral vectors, viral vector vaccines
37.0% critical · 58.9% positiveLife Sciences coverage across Netherlands. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Researchers discuss challenges in using microbes and plant systems for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Papers highlight microbial risks and nutritional impacts of modern food processing techniques.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Studies examine hurdles in controlling gene activity and mRNA applications across cell and animal models.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Research points to difficulties in improving nutrient uptake and breeding crops for resilient food supplies.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Works address obstacles in integrating pest control, host resistance, and pathogen dynamics.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Literature outlines the spread of drug‑resistant microbes in humans, livestock, and the environment.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Papers cover a range of unrelated topics from molecular order to interdisciplinary analyses.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Authors caution about oxidative stress and viability when using microplastics or advanced cell‑painting assays.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Studies warn of complexities in applying genomic prediction to plant breeding and sustainable livestock feeding.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Research advises careful evaluation of bioactive feed compounds and plant‑protein replacements for animal health.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Papers highlight safety concerns surrounding caffeine levels and novel insect‑derived food colorants.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Works emphasize the need for precise interpretation of gene expression and repair pathways in disease contexts.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Authors discuss unintended resistance development from combined antibiotic, biocide, and metal exposures.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Studies caution about dose strategies and biological control alternatives to mitigate evolving pesticide resistance.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Research explores novel antibodies, fluorescence methods, and flow cytometry for improved in‑vivo diagnostics.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Papers identify promising gene knockdown and apoptosis pathways for disease treatment and metabolic control.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Works highlight health‑promoting ingredients and antioxidant properties of emerging plant‑derived food products.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Studies present innovative DNA methylation and messenger RNA techniques for detecting disease‑related biomarkers.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Research showcases plant‑derived antimicrobials and microbial metabolites as new strategies against resistant pathogens.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Papers discuss leveraging germplasm and quantitative trait loci to boost yield and desirable characteristics.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Works focus on microbial fermentation and by‑product valorization for greener agriculture and energy.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.2% |
| Promising | 30.4% | 37.2% |
| Breakthrough | 14.1% | 27.1% |
| Problem-identifying | 8.3% | 9.2% |
| Cautionary | 3.5% | 4.5% |
| Comparative | 2.4% | 3.8% |
| Critical | 1.0% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
25.5% across the displayed hubs
15 companies hiring · $1.4B disclosed funding
Explore companies in Amsterdam ↗
15.8% across the displayed hubs
10 companies hiring · $1.5B disclosed funding
Explore companies in Leiden ↗
13.4% across the displayed hubs
6 companies hiring · $777.9M disclosed funding
Explore companies in Utrecht ↗
11.6% across the displayed hubs
4 companies hiring · $322.7M disclosed funding
Explore companies in Nijmegen ↗
9.5% across the displayed hubs
4 companies hiring · $405.7M disclosed funding
Explore companies in Eindhoven ↗
8.6% across the displayed hubs
3 companies hiring · $51.4M disclosed funding
Explore companies in Groningen ↗
8.4% across the displayed hubs
5 companies hiring · $163.8M disclosed funding
Explore companies in Delft ↗
7.3% across the displayed hubs
2 companies hiring · $40.0M disclosed funding
Explore companies in Maastricht ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗